Biopsy remains the gold standard for diagnosing nonalcoholic steatohepatitis (NASH). However, the great need for noninvasive tests to risk stratify patients with nonalcoholic fatty liver disease (NAFLD) is beginning to be met, as reflected in the proceedings of The Liver Meeting® 2021, the annual meeting of the American Association for the Study of Liver Diseases (AASLD).
Following these proceedings, featured expert Rohit Loomba, MD, MHSc, was interviewed by Conference Reporter Editor-in-Chief Tom Iarocci, MD. Dr Loomba’s clinical perspectives are presented here.